Vigabatrin-associated retinal cone system dysfunction: Electroretinogram and ophthalmologic findings

Neurology

Volumn 50, Issue 3, 1998, Pages 614-618

  Krauss, Gregory L ^a,d   Johnson, Mary A ^b   Miller, Neil R ^a,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; VIGABATRIN;

ADULT; AGED; ARTICLE; CASE REPORT; CONTROLLED STUDY; ELECTRORETINOGRAPHY; EPILEPSY; EVOKED VISUAL RESPONSE; FEMALE; HUMAN; MALE; OPHTHALMOSCOPY; PRIORITY JOURNAL; RETINA AMACRINE CELL; RETINA ARTERY; RETINA CONE; RETINA DISEASE; VISUAL DISORDER; VISUAL FIELD DEFECT;

EID: 0031921006     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.50.3.614     Document Type: Article

References (30)

1. Ben-Menachem E. Vigabatrin. Epilepsia 1995;36(suppl 2): S95-S104.
2. French J, Mosier M, Walker S, Somerville K, Sussman N. A double-blind placebo controlled study of vigabatrin 32 g/day in patients with uncontrolled complex partial seizures. Neurology 1996;46:54-61.
3. Marson AG, Kadir ZA, Hutton JL, Chadwick DW. The new antiepileptic drugs: a systemic review of their efficacy and tolerability. Epilepsia 1997;38:859-880.
4. Butler WH. The neuropathology of vigabatrin. Epilepsia 1989; 30(suppl 3):S15-S17.
5. Gibson JP, Yarrington JT, Loudy DE, et al. Chronic toxicity studies with vigabatrin, a GABA-transaminase inhibitor. Toxicol Pathol 1990;18:225-238.
6. Fisher RS, Kerrigan JF. Vigabatrin: toxicity. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995:931-939.
7. John RA, Rimmer EM, Williams J, et al. Micro-vacuolation in rat brains after long term administration of GABA-transaminase inhibitors. Comparison of effects of ethanolamine-O-sulphase and vigabatrin. Biochem Pharmacol 1987;36:1467-1473.
8. Cocito L, Maffini M, Loeb C. MRI findings in epileptic patients on vigabatrin for more than five years. Seizure 1992;1:163-165.
9. Mauguiere F, Chauvel P, Dewailly J, Dousse N. No effect of long-term vigabatrin treatment on central nervous system conduction in patients with refractory epilepsy: results of a multicenter study of somatosensory and visual evoked potentials. PMS Study Multicenter Group. Epilepsia 1997;38:301-308.
10. Elke T, Talbot JF, Lawden MC. Severe persistent visual field constriction associated with vigabatrin. Br Med J 1997;314: 180-181.
11. Wilson EA, Brodie MJ. Severe persistent visual field constriction associated with vigabatrin. Br Med J 1997;314:1693.
12. Wong IC, Mawer GE, Sander JW. Severe persistent visual field constriction associated with vigabatrin. Br Med J 1997; 314:1693-1694.
13. Blackwell N, Hayllar J, Kelly G. Severe persistent visual field constriction associated with vigabatrin. Br Med J 1997;314: 1694.
14. Harding GF. Severe persistent visual field constriction associated with vigabatrin. Br Med J 1997;314:1694.
15. Hood DC, Birch DG. Light adaptation of human rod receptors: the leading edge of human a-wave and models of rod receptor activity. Vis Res 1993;33:1605-1618.
16. Breton ME, Schueller A, Lamb T, Pugh EN Jr. Analysis of ERG a-wave amplification and kinetics in terms of the G-protein cascade of phototransduction. Invest Ophthalmol Vis Sci 1994;35:295-309.
17. Kramer G, Scollo-Lavizzari G, Jallon P, et al. Vigabatrin-associated bilateral concentric visual field defects in four patients. Epilepsia 1997;38(suppl 8):179. Abstract.
18. Petroff OA, Rothman DL, Behar KL, Collins TL, Mattson RH. Human brain GABA levels rise rapidly after initiation of vigabatrin therapy. Neurology 1996;47:1567-1571.
19. Pourcho RG, Goebal DJ. Neuronal subpopulations in cat retina which accumulate the GABA agonist [3H] muscimol: a combined Golgi and autoradiographic study. J Comp Neurol 1983;219:25-35.
20. Brecha N, Johnson J, Khuon T, Evans C, Rickman D. Multiple GABA plasma membrane transporters are expressed in the vertebrate retina. Invest Ophthalmol Vis Sci 1995; 36(suppl):S214.
21. Jasoni CL, Hendrickson AE. Distribution of glutamic acid decarboxylase (GAD) mRNA-expressing cells in primate retina. Invest Ophthalmol Vis Sci 1995;36(suppl):S286.
22. Haesendonck EC, Missotten L. A subgroup of bipolar cells in human retina is GABA-immunoreactive. Neurosci Lett. 1993; 161:187-190.
23. Huang B, Redburn DA. GABA-Induced calcium responses in the outer retina of neonatal rabbits. Invest Ophthalmol Vis Sci 1995;36(suppl):S214.
24. Gottlob I, Wundsch L, Tuppy FK. The rabbit electroretinogram: effect of GABA and its antagonists. Vis Res 1988;28: 203-210.
25. Bayer A, Zrenner E, Reid S, Schmidt D. Effects of anticonvulsant drugs on retinal function. Psychophysical and electrophysiological findings in patients with epilepsy. Invest Ophthalmol Vis Sci 1990;31(suppl):427.
26. Bush RA. Sieving PA. Inner retinal contributions to the primate photopic fast flicker electroretinogram. Journal of the Optical Society of America A-Optics & Image Science. 1996; 13:557-565.
27. Grignolo A, Orzalesi N, Castellazzo R, et al. Retinal damage by visible light in albino rats. Opththalmologica 1969;157:43-59.
28. Crofts K, Brennan R, Kearney P, O'Connor G. Vigabatrin-induced optic neuropathy. J Neurol 1997;10:666-667.
29. Steinhoff BJ, Freudenthaler N, Paulus W. The influence of established and new antiepileptic drugs on visual perception. 1. A placebo-controlled, double-blind, single-dose study in healthy volunteers. Epilepsy Res 1997;29:35-47.
30. Steinhoff BJ, Freudenthaler N, Paulus W. The influence of established and new antiepileptic drugs on visual perception. II. A controlled study in patients with epilepsy under long-term antiepileptic medication. Epilepsy Res 1997;29:49-58.